rolipram has been researched along with Hypersensitivity in 7 studies
Hypersensitivity: Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigates the role of adrenal-derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)-4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice." | 7.70 | Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. ( Chapman, RW; Crawley, Y; Kreutner, W; Kung, TT; Luo, B; Young, S, 2000) |
| "This study investigates the role of adrenal-derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)-4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice." | 3.70 | Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. ( Chapman, RW; Crawley, Y; Kreutner, W; Kung, TT; Luo, B; Young, S, 2000) |
| "A new guinea pig model of allergic asthma was used to investigate the effects of low doses of the phosphodiesterase inhibitors, rolipram (phosphodiesterase IV selective), ORG 20241 (N-hydroxy-4-(3,4-dimethoxyphenyl)-thiazole-2-carboximidamide; dual phosphodiesterase III/IV inhibitor with some selectivity for the phosphodiesterase IV isoenzyme), and of theophylline (non-selective) on allergen-induced early and late phase asthmatic reactions, bronchial hyperreactivity to histamine inhalation, and airway inflammation." | 3.69 | Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. ( Meurs, H; Olymulder, CG; Santing, RE; Van der Molen, K; Zaagsma, J, 1995) |
| "Rolipram was given orally to the animals daily from days 0-20." | 1.33 | Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice. ( Alam, AH; Hossain, MA; Takano, H; Taneda, S; Yamaki, K; Yanagisawa, R; Yoshino, S, 2005) |
| "Rolipram and RP 73401 were equally effective and potent when given by the oral route and much more active than the PDE4 inhibitor CDP 840." | 1.30 | A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin. ( Cooper, N; Gristwood, RW; Hellewell, PG; Miotla, JM; Teixeira, MM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Weishaar, RE | 1 |
| Cain, MH | 1 |
| Bristol, JA | 1 |
| Nunes, IKDC | 1 |
| de Souza, ET | 1 |
| Martins, IRR | 1 |
| Barbosa, G | 1 |
| Moraes Junior, MO | 1 |
| Medeiros, MM | 1 |
| Silva, SWD | 1 |
| Balliano, TL | 1 |
| da Silva, BA | 1 |
| Silva, PMR | 1 |
| Carvalho, VF | 1 |
| Martins, MA | 1 |
| Lima, LM | 1 |
| Bopp, T | 1 |
| Dehzad, N | 1 |
| Reuter, S | 1 |
| Klein, M | 1 |
| Ullrich, N | 1 |
| Stassen, M | 1 |
| Schild, H | 1 |
| Buhl, R | 1 |
| Schmitt, E | 1 |
| Taube, C | 1 |
| Yamaki, K | 1 |
| Alam, AH | 1 |
| Hossain, MA | 1 |
| Taneda, S | 1 |
| Yanagisawa, R | 1 |
| Takano, H | 1 |
| Yoshino, S | 1 |
| Santing, RE | 1 |
| Olymulder, CG | 1 |
| Van der Molen, K | 1 |
| Meurs, H | 1 |
| Zaagsma, J | 1 |
| Teixeira, MM | 1 |
| Miotla, JM | 1 |
| Cooper, N | 1 |
| Gristwood, RW | 1 |
| Hellewell, PG | 1 |
| Kung, TT | 1 |
| Crawley, Y | 1 |
| Luo, B | 1 |
| Young, S | 1 |
| Kreutner, W | 1 |
| Chapman, RW | 1 |
1 review available for rolipram and Hypersensitivity
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; | 1985 |
6 other studies available for rolipram and Hypersensitivity
| Article | Year |
|---|---|
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; H | 2020 |
Inhibition of cAMP degradation improves regulatory T cell-mediated suppression.
Topics: Animals; Cells, Cultured; Coculture Techniques; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Ty | 2009 |
Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Animals; Cells, Cultured; Cyclic Nucleo | 2005 |
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Inhalation; Analysis of Variance; Animals; Asth | 1995 |
A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Eosinoph | 1997 |
Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.
Topics: Animals; Antihypertensive Agents; Bronchial Hyperreactivity; Bronchoalveolar Lavage; Catecholamines; | 2000 |